Latest & greatest articles for gabapentin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on gabapentin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on gabapentin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for gabapentin

41. Gabapentin tablets versus capsules: a review of the evidence regarding appropriate use

Gabapentin tablets versus capsules: a review of the evidence regarding appropriate use Gabapentin tablets versus capsules: a review of the evidence regarding appropriate use Gabapentin tablets versus capsules: a review of the evidence regarding appropriate use Canadian Agency for Drugs and Technologies in Health Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made (...) for the HTA database. Citation Canadian Agency for Drugs and Technologies in Health. Gabapentin tablets versus capsules: a review of the evidence regarding appropriate use. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). 2010 Authors' conclusions There is a paucity of primary studies comparing the potential for misuse of gabapentin capsules and tablets. There is evidence from case reports that gabapentin capsules may be subject to misuse in certain populations, particularly those

2010 Health Technology Assessment (HTA) Database.

42. Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial. (Abstract)

Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial. Drugs for neuropathic pain have incomplete efficacy and dose-limiting side-effects when given as monotherapy. We assessed the efficacy and tolerability of combined nortriptyline and gabapentin compared with each drug given alone.In this double-blind, double-dummy, crossover trial, patients with diabetic polyneuropathy or postherpetic neuralgia, and who had a daily (...) pain score of at least 4 (scale 0-10), were enrolled and treated at one study site in Canada between Nov 5, 2004, and Dec 13, 2007. 56 patients were randomised in a 1:1:1 ratio with a balanced Latin square design to receive one of three sequences of daily oral gabapentin, nortriptyline, and their combination. In sequence, a different drug was given to each randomised group in three treatment periods. During each 6-week treatment period, drug doses were titrated towards maximum tolerated dose

2009 Lancet Controlled trial quality: predicted high

43. Gabapentin for the treatment of hot flashes in women with natural or tamoxifen-induced menopause: a systematic review and meta-analysis

Gabapentin for the treatment of hot flashes in women with natural or tamoxifen-induced menopause: a systematic review and meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

44. Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain

Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

45. Gabapentin versus tricyclic antidepressants for diabetic neuropathy and post-herpetic neuralgia: discrepancies between direct and indirect meta-analyses of randomized controlled trials

Gabapentin versus tricyclic antidepressants for diabetic neuropathy and post-herpetic neuralgia: discrepancies between direct and indirect meta-analyses of randomized controlled trials Gabapentin versus tricyclic antidepressants for diabetic neuropathy and post-herpetic neuralgia: discrepancies between direct and indirect meta-analyses of randomized controlled trials Gabapentin versus tricyclic antidepressants for diabetic neuropathy and post-herpetic neuralgia: discrepancies between direct (...) and indirect meta-analyses of randomized controlled trials Chou R, Carson S, Chan B K CRD summary This review concluded that there was no difference in pain relief between gabapentin and tricyclic antidepressants in patients with diabetic neuropathy or post-herpetic neuralgia, although direct evidence was limited. The review was well conducted and these findings are likely to be reliable. Authors' objectives To compare gabapentin with tricyclic antidepressants for the treatment of diabetic neuropathy

2009 DARE.

46. Treatment of fibromyalgia syndrome with gabapentin and pregabalin: a meta-analysis of randomized controlled trials

Treatment of fibromyalgia syndrome with gabapentin and pregabalin: a meta-analysis of randomized controlled trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

47. Gabapentin for pain: New evidence from hidden data

Gabapentin for pain: New evidence from hidden data [75] Gabapentin for pain: New evidence from hidden data | Therapeutics Initiative Independent Healthcare Evidence > > [75] Gabapentin for pain: New evidence from hidden data Background Gabapentin (Neurontin) was licensed in Canada in 1993 for adjunctive treatment of epilepsy. In 1998 two double blind randomized controlled trials (DBRCT) suggested mild analgesic effects of gabapentin in painful diabetic peripheral neuropathy (PDPN) and post (...) -herpetic neuralgia (PHN) . Subsequently, unapproved use of gabapentin exploded for pain, migraine, and even as a “mood stabilizer”. (Jan-Feb 2000) reviewed gabapentin for pain. It noted that gabapentin is eliminated by kidney filtration (half-life 6 hours with normal renal function) and that it reduced pain by a mean of 1-2 points on a pain score of 0-10, over 2 weeks, NNT=4 for “moderate or marked” benefit. The Letter concluded: “Gabapentin benefits at best a minority of patients with painful diabetic

2009 Therapeutics Letter

48. Gabapentin does not reduce post-thoracotomy shoulder pain: a randomized, double-blind placebo-controlled study Full Text available with Trip Pro

Gabapentin does not reduce post-thoracotomy shoulder pain: a randomized, double-blind placebo-controlled study Despite adequate epidural analgesia, up to 97% of patients undergoing thoracotomy experience ipsilateral shoulder pain. In this setting, this study evaluated the safety and the efficacy of pre-emptive gabapentin.A double-blind, placebo-controlled study was undertaken in 51 patients randomized into two groups. Two hours before surgery, 23 patients received gabapentin 1200 mg po (Group G (...) in Group P had sedation scores > 1, compared to 0/28 patients in Group G (P = 0.05).Pre-emptively administered gabapentin, 1200 mg, does not reduce the incidence, or the severity, of post-thoracotomy shoulder pain in patients receiving thoracic epidural analgesia.

2008 EvidenceUpdates Controlled trial quality: uncertain

49. Cost-effectiveness analysis of a lidocaine 5% medicated plaster compared with gabapentin and pregabalin for treating postherpetic neuralgia: a German perspective

Cost-effectiveness analysis of a lidocaine 5% medicated plaster compared with gabapentin and pregabalin for treating postherpetic neuralgia: a German perspective Cost-effectiveness analysis of a lidocaine 5% medicated plaster compared with gabapentin and pregabalin for treating postherpetic neuralgia: a German perspective Cost-effectiveness analysis of a lidocaine 5% medicated plaster compared with gabapentin and pregabalin for treating postherpetic neuralgia: a German perspective Liedgens H (...) , Hertel N, Gabriel A, Nuijten M, Dakin H, Mitchell S, Poulsen Nautrup B Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to examine the cost-effectiveness of the lidocaine 5% medicated plaster versus gabapentin

2008 NHS Economic Evaluation Database.

50. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Full Text available with Trip Pro

The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Carbamazepine is widely accepted as a drug of first choice for patients with partial onset seizures. Several newer drugs possess efficacy against these seizure types but previous randomised controlled trials have failed to inform a choice between these drugs. We aimed to assess efficacy with regards to longer-term (...) outcomes, quality of life, and health economic outcomes.SANAD was an unblinded randomised controlled trial in hospital-based outpatient clinics in the UK. Arm A recruited 1721 patients for whom carbamazepine was deemed to be standard treatment, and they were randomly assigned to receive carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate. Primary outcomes were time to treatment failure, and time to 12-months remission, and assessment was by both intention to treat and per protocol

2007 Lancet Controlled trial quality: predicted high

51. Use of gabapentin for perioperative pain control: a meta-analysis

Use of gabapentin for perioperative pain control: a meta-analysis Use of gabapentin for perioperative pain control: a meta-analysis Use of gabapentin for perioperative pain control: a meta-analysis Peng P W, Wijeysundera D N, Li C C CRD summary This generally well-conducted review assessed the use of gabapentin for peri-operative pain control in adults. The authors concluded that gabapentin is associated with a reduction in pain, analgesic consumption and opioid-related side-effects (...) , but there is an increased risk of dizziness and sedation. These conclusions appear to be supported by the data presented, although there may be some risk of publication bias. Authors' objectives To assess the analgesic effectiveness, opioid-sparing effects and side-effects of gabapentin used peri-operatively. Searching MEDLINE (1966 to February 2006), EMBASE (1980 to February 2006), the Cochrane Controlled Trials Register (Issue 1, 2006), Science Citation Index, Current Controlled Trials Register, TextMed, Science

2007 DARE.

52. Cost-effectiveness analysis of pregabalin versus gabapentin in the management of neuropathic pain due to diabetic polyneuropathy or post-herpetic neuralgia

Cost-effectiveness analysis of pregabalin versus gabapentin in the management of neuropathic pain due to diabetic polyneuropathy or post-herpetic neuralgia Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2007 NHS Economic Evaluation Database.

53. Cost-effectiveness of a lidocaine 5% medicated plaster relative to gabapentin for postherpetic neuralgia in the United Kingdom

Cost-effectiveness of a lidocaine 5% medicated plaster relative to gabapentin for postherpetic neuralgia in the United Kingdom Cost-effectiveness of a lidocaine 5% medicated plaster relative to gabapentin for postherpetic neuralgia in the United Kingdom Cost-effectiveness of a lidocaine 5% medicated plaster relative to gabapentin for postherpetic neuralgia in the United Kingdom Dakin H, Nuijten M, Liedgens H, Poulsen Nautrup B Record Status This is a critical abstract of an economic evaluation (...) that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to assess the cost-effectiveness of lidocaine 5% medicated plasters in place of gabapentin in the treatment of postherpetic neuralgia, in patients who had insufficient pain relief with standard analgesics and who could not tolerate, or had

2007 NHS Economic Evaluation Database.

54. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial

The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2007 NHS Economic Evaluation Database.

55. Narrative review: the promotion of gabapentin: an analysis of internal industry documents. (Abstract)

Narrative review: the promotion of gabapentin: an analysis of internal industry documents. Internal documents from the pharmaceutical industry provide a unique window for understanding the structure and methods of pharmaceutical promotion. Such documents have become available through litigation concerning the promotion of gabapentin (Neurontin, Pfizer, Inc., New York, New York) for off-label uses.To describe how gabapentin was promoted, focusing on the use of medical education, research (...) , and publication.Court documents available to the public from United States ex. rel David Franklin vs. Pfizer, Inc., and Parke-Davis, Division of Warner-Lambert Company, mostly from 1994-1998.All documents were reviewed by 1 author, with selected review by coauthors. Marketing strategies and tactics were identified by using an iterative process of review, discussion, and re-review of selected documents.The promotion of gabapentin was a comprehensive and multifaceted process. Advisory boards, consultants meetings

2006 Annals of Internal Medicine

56. Gabapentin and postoperative pain: a systematic review of randomized controlled trials

Gabapentin and postoperative pain: a systematic review of randomized controlled trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2006 DARE.

57. The analgesic effects of perioperative gabapentin on postoperative pain: a meta-analysis

The analgesic effects of perioperative gabapentin on postoperative pain: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2006 DARE.

58. The Use of Gabapentin and Tricyclic Antidepressants in the Treatment of Neuropathic Pain in Cancer Patients

The Use of Gabapentin and Tricyclic Antidepressants in the Treatment of Neuropathic Pain in Cancer Patients Evidence-Based Series 13-8 EDUCATION AND INFORMATION 2013 A Quality Initiative of the Program in Evidence-based Care (PEBC), Cancer Care Ontario (CCO) The Use of Gabapentin and Tricyclic Antidepressants in the Treatment of Neuropathic Pain in Cancer Patients L. Librach, N. Lloyd, V. Jarvis, D. Warr, A. R. Jadad, J. Wilson, M. Brouwers, R. Wong, and members of the Supportive Care (...) @mcmaster.ca EBS Citation (Vancouver Style): Librach L, Lloyd N, Jarvis V, Warr D, Jadad AR, Wilson J, et al. The use of gabapentin and tricyclic antidepressants in the treatment of neuropathic pain in cancer patients. Toronto (ON): Cancer Care Ontario; 2006 Oct 11 [Education and Information 2011 Sep]. Program in Evidence-based Care Evidence-based Series: 13-8 Education and Information 2013 EBS 13-8 EDUCATION AND INFORMATION 2013 PRACTICE GUIDELINE – page 1 Evidence-based Series #13-8: Section 1 The Use

2006 Cancer Care Ontario

59. Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial. Full Text available with Trip Pro

Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial. Most women receiving systemic therapy for breast cancer experience hot flashes. We undertook a randomised, double-blind, placebo-controlled, multi-institutional trial to assess the efficacy of gabapentin in controlling hot flashes in women with breast cancer.420 women with breast cancer who were having two or more hot flashes per day were randomly assigned placebo, gabapentin 300 mg (...) /day, or gabapentin 900 mg/day by mouth in three divided doses for 8 weeks. Each patient kept a 1-week, self-report diary on the frequency, severity, and duration of hot flashes before the start of the study and during weeks 4 and 8 of treatment. Analyses were by intention to treat.Evaluable data were available on 371 participants at 4 weeks (119 placebo, 123 gabapentin 300 mg, and 129 gabapentin 900 mg) and 347 at 8 weeks (113 placebo, 114 gabapentin 300 mg, and 120 gabapentin 900 mg

2005 Lancet Controlled trial quality: predicted high

60. Morphine, gabapentin, or their combination for neuropathic pain. Full Text available with Trip Pro

Morphine, gabapentin, or their combination for neuropathic pain. The available drugs to treat neuropathic pain have incomplete efficacy and dose-limiting adverse effects. We compared the efficacy of a combination of gabapentin and morphine with that of each as a single agent in patients with painful diabetic neuropathy or postherpetic neuralgia.In this randomized, double-blind, active placebo-controlled, four-period crossover trial, patients received daily active placebo (lorazepam), sustained (...) -release morphine, gabapentin, and a combination of gabapentin and morphine--each given orally for five weeks. The primary outcome measure was mean daily pain intensity in patients receiving a maximal tolerated dose; secondary outcomes included pain (rated according to the Short-Form McGill Pain Questionnaire), adverse effects, maximal tolerated doses, mood, and quality of life.Of 57 patients who underwent randomization (35 with diabetic neuropathy and 22 with postherpetic neuralgia), 41 completed

2005 NEJM Controlled trial quality: predicted high